MongoDB, Inc. (MDB) Reaches $26.87 After 7.00% Up Move; Argos Therapeutics (ARGS) Shorts Up By 106.67%

December 6, 2017 - By Vivian Currie

Argos Therapeutics Incorporated (NASDAQ:ARGS) had an increase of 106.67% in short interest. ARGS’s SI was 5.59 million shares in December as released by FINRA. Its up 106.67% from 2.71 million shares previously. With 1.86 million avg volume, 3 days are for Argos Therapeutics Incorporated (NASDAQ:ARGS)’s short sellers to cover ARGS’s short positions. The SI to Argos Therapeutics Incorporated’s float is 26.03%. The stock decreased 3.32% or $0.01 during the last trading session, reaching $0.16. About 1.81 million shares traded. Argos Therapeutics, Inc. (NASDAQ:ARGS) has declined 92.57% since December 6, 2016 and is downtrending. It has underperformed by 109.27% the S&P500.

The stock of MongoDB, Inc. (NASDAQ:MDB) is a huge mover today! The stock increased 2.75% or $0.72 during the last trading session, reaching $26.87. About 398,184 shares traded. MongoDB, Inc. (NASDAQ:MDB) has 0.00% since December 6, 2016 and is . It has underperformed by 16.70% the S&P500.The move comes after 8 months positive chart setup for the $1.32 billion company. It was reported on Dec, 6 by Barchart.com. We have $28.75 PT which if reached, will make NASDAQ:MDB worth $92.12M more.

MongoDB, Inc. operates as a general purpose database platform worldwide. The company has market cap of $1.32 billion. It offers MongoDB Enterprise Advanced, a subscription package for enterprise clients to run in the cloud or in a hybrid environment; MongoDB Atlas, a cloud hosted database-as-a-service solution; Community Server, a free-to-download version of its database, which includes the functionality that developers need to get started with MongoDB; and MongoDB Stitch, a backend-as-a-service designed to simplify application development. It currently has negative earnings. The firm also provides professional services, such as consulting and training.

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Argos Therapeutics had 6 analyst reports since November 16, 2015 according to SRatingsIntel. JMP Securities maintained Argos Therapeutics, Inc. (NASDAQ:ARGS) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $12 target. The firm earned “Buy” rating on Tuesday, November 17 by Needham. FBR Capital maintained Argos Therapeutics, Inc. (NASDAQ:ARGS) rating on Thursday, August 11. FBR Capital has “Outperform” rating and $13 target. The company was maintained on Tuesday, April 19 by Roth Capital. The company was maintained on Thursday, September 21 by Needham. The stock of Argos Therapeutics, Inc. (NASDAQ:ARGS) earned “Outperform” rating by FBR Capital on Monday, November 16.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $14.09 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Investors sentiment decreased to 0.54 in Q2 2017. Its down 0.61, from 1.15 in 2017Q1. It dived, as 13 investors sold Argos Therapeutics, Inc. shares while 15 reduced holdings. 9 funds opened positions while 6 raised stakes. 1.91 million shares or 42.00% less from 3.30 million shares in 2017Q1 were reported. Moreover, Citadel Advsrs Ltd Liability has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 17,989 shares. Stifel Financial Corporation reported 65,550 shares. Moreover, Blackrock has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 6,256 shares. Manufacturers Life Ins The holds 0% or 1,050 shares. Citigroup Incorporated, New York-based fund reported 1 shares. Goldman Sachs Group Incorporated holds 0% or 110,181 shares. California Employees Retirement Sys reported 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Millennium Mgmt Lc holds 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 193,294 shares. Susquehanna Intl Limited Liability Partnership has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 31,271 shares. Geode Mgmt Limited Liability Corporation owns 129,046 shares. Moreover, Deutsche State Bank Ag has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 736 shares. Morgan Stanley stated it has 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Meeder Asset Mngmt invested 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS). Hightower Advisors Ltd Limited Liability Company, Illinois-based fund reported 32,071 shares. Paloma Partners Mngmt reported 46,100 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Currie




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: